Summary

Peptide Therapeutics Contract API Manufacturing Market – Scope of Report
TMR’s report on the global peptide therapeutics contract API manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global peptide therapeutics contract API manufacturing market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics contract API manufacturing market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics contract API manufacturing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics contract API manufacturing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide therapeutics contract API manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics contract API manufacturing market.

The report delves into the competitive landscape of the global peptide therapeutics contract API manufacturing market. Key players operating in the global peptide therapeutics contract API manufacturing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide therapeutics contract API manufacturing market profiled in this report.

Key Questions Answered in Global peptide therapeutics contract API manufacturing Market Report
• What is the sales/revenue generated by peptide therapeutics contract API manufacturing across all regions during the forecast period?
• What are the opportunities in the global peptide therapeutics contract API manufacturing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Peptide Therapeutics Contract API Manufacturing Market – Research Objectives and Research Approach
The comprehensive report on the global peptide therapeutics contract API manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide therapeutics contract API manufacturing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide therapeutics contract API manufacturing market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Peptide Therapeutics Contract API Manufacturing Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Scale of Operation
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Scale of Operation, 2020-2034
6.3.1. Preclinical/Clinical
6.3.2. Commercial
6.4. Market Attractiveness Analysis, by Scale of Operation
7. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Type of Synthesis Method Used
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
7.3.1. Non-chemical Synthesis Method
7.3.2. Chemical Synthesis Method
7.4. Market Attractiveness Analysis, by Type of Synthesis Method Used
8. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Enterprise Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Enterprise Type, 2020-2034
8.3.1. Large Enterprise
8.3.2. Small and Medium Enterprise
8.4. Market Attractiveness Analysis, by Enterprise Type
9. Global Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Scale of Operation, 2020-2034
10.3.1. Preclinical/Clinical
10.3.2. Commercial
10.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
10.4.1. Non-chemical Synthesis Method
10.4.2. Chemical Synthesis Method
10.5. Market Value Forecast, by Enterprise Type, 2020-2034
10.5.1. Large Enterprise
10.5.2. Small and Medium Enterprise
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Scale of Operation
10.7.2. By Type of Synthesis Method Used
10.7.3. By Enterprise Type
10.7.4. By Country
11. Europe Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Scale of Operation, 2020-2034
11.3.1. Preclinical/Clinical
11.3.2. Commercial
11.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
11.4.1. Non-chemical Synthesis Method
11.4.2. Chemical Synthesis Method
11.5. Market Value Forecast, by Enterprise Type, 2020-2034
11.5.1. Large Enterprise
11.5.2. Small and Medium Enterprise
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Scale of Operation
11.7.2. By Type of Synthesis Method Used
11.7.3. By Enterprise Type
11.7.4. By Country/Sub-region
12. Asia Pacific Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Scale of Operation, 2020-2034
12.3.1. Preclinical/Clinical
12.3.2. Commercial
12.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
12.4.1. Non-chemical Synthesis Method
12.4.2. Chemical Synthesis Method
12.5. Market Value Forecast, by Enterprise Type, 2020-2034
12.5.1. Large Enterprise
12.5.2. Small and Medium Enterprise
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Scale of Operation
12.7.2. By Type of Synthesis Method Used
12.7.3. By Enterprise Type
12.7.4. By Country/Sub-region
13. Latin America Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Scale of Operation, 2020-2034
13.3.1. Preclinical/Clinical
13.3.2. Commercial
13.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
13.4.1. Non-chemical Synthesis Method
13.4.2. Chemical Synthesis Method
13.5. Market Value Forecast, by Enterprise Type, 2020-2034
13.5.1. Large Enterprise
13.5.2. Small and Medium Enterprise
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Scale of Operation
13.7.2. By Type of Synthesis Method Used
13.7.3. By Enterprise Type
13.7.4. By Country/Sub-region
14. Middle East & Africa Peptide Therapeutics Contract API Manufacturing Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Scale of Operation, 2020-2034
14.3.1. Preclinical/Clinical
14.3.2. Commercial
14.4. Market Value Forecast, by Type of Synthesis Method Used, 2020-2034
14.4.1. Non-chemical Synthesis Method
14.4.2. Chemical Synthesis Method
14.5. Market Value Forecast, by Enterprise Type, 2020-2034
14.5.1. Large Enterprise
14.5.2. Small and Medium Enterprise
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Scale of Operation
14.7.2. By Type of Synthesis Method Used
14.7.3. By Enterprise Type
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Ambiopharm Inc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Auspep
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Bachem Holding AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. BCN Peptides
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Chinese Peptide Company
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. CordenPharma
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. CPC Scientific
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Creative Peptides
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. CSBio
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Hybio Pharmaceutical
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Peptide Institute, Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. PolyPeptide Group
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. ScinoPharm
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Senn Chemicals AG
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview